We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Amylyx

News List

Amylyx Pharma plans to file ALS therapy with the EMA this year pharmatimes
April 16, 2021
Amylyx Pharmaceuticals has announced its intention to submit a marketing authorisation application for its investigational amyotrophic lateral sclerosis (ALS) therapy AMX0035 to the European Medicines Agency (EMA) by the end of 2021.
Amylyx announces FDA granted orphan drug designation for AMX0035 to treat Wolfram syndrome pharmaceutical-business-review
November 19, 2020
Amylyx Pharmaceuticals announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to AMX0035 for the treatment of Wolfram syndrome.
Amylyx Pharmaceuticals announces AMX0035 demonstrated statistically significant treatment benefit in ALS in CENTAUR trial pharmaceutical-business-review
December 20, 2019
Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases ...